Genomic arrays in chronic lymphocytic leukemia routine clinical practice: Are we ready to substitute conventional cytogenetics and fluorescence in situ hybridization techniques?

Leukemia and Lymphoma

Volumn 54, Issue 5, 2013, Pages 986-995

  Puiggros, Anna ^a   Puigdecanet, Eulàlia ^b   Salido, Marta ^a,c   Ferrer, Ana ^a,d   Abella, Eugènia ^c   Gimeno, Eva ^c   Nonell, Lara ^b   Herranz, María José ^e   Galván, Ana Belén ^c   Rodríguez Rivera, María ^a,c   Melero, Carme ^c   Pairet, Silvia ^c   Bellosillo, Beatriz ^c   Serrano, Sergi ^c,d   Florensa, Lourdes ^a,d   Solé, Francesc ^a,c   Espinet, Blanca ^a,c  

^a Programa de Recerca en Càncer   (Spain)

^b Secció Microbiología   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d Soledad Woessner IMAS   (Spain)

^e Hospital de Sant Pau i Santa Tecla   (Spain)

Author keywords

Chronic lymphocytic leukemia; Conventional G banding cytogenetics; FISH; Genomic arrays

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; COPY NUMBER VARIATION; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; G BANDING CYTOGENETICS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRISOMY 12;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; GENOMICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED;

EID: 84876209057     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.731598     Document Type: Article

References (37)

1. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
2. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
3. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
4. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105-111.
5. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
6. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323:720-724.
7. Dicker F, Schnittger S, Haferlach T, et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006; 108:3152-3160.
8. Put N, Konings P, Rack K, et al. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer 2009; 48: 843-853.
9. Schwaenen C, Nessling M, Wessendorf S, et al. Automated array-based genomic prof ling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA 2004;101:1039-1044.
10. Sargent R, Jones D, Abruzzo LV, et al. Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic prof ling of chronic lymphocytic leukemia. J Mol Diagn 2009;11:25-34.
11. Kujawski L, Ouillette P, Erba H, et al. Genomic complexity identif es patients with aggressive chronic lymphocytic leukemia. Blood 2008;112:1993-2003.
12. Gunnarsson R, Staaf J, Jansson M, et al. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia- A comparative study of four Differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008; 47:697-711.
13. Kay NE, Eckel-Passow JE, Braggio E, et al. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet 2010;203:161-168.
14. Ouillette P, Collins R, Shakhan S, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 2011;118:3051-3061.
15. Ouillette P, Erba H, Kujawski L, et al. Integrated genomic prof ling of chronic lymphocytic leukemia identif es subtypes of deletion 13q14. Cancer Res 2008; 68: 1012-1021.
16. Chapiro E, Leporrier N, Radford-Weiss I, et al. Gain of the shortarm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. Leuk Res 2010;34:63-68.
17. Mosca L, Fabris S, Lionetti M, et al. Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. Clin Cancer Res 2010; 16: 5641-5653.
18. Parker H, Rose-Zerilli MJ, Parker A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia 2011; 25: 489-497.
19. Rinaldi A, Mian M, Kwee I, et al. Genome-wide DNA prof ling better defines the prognosis of chronic lymphocytic leukaemia. Br J Haematol 2011;154:590-599.
20. Rodriguez AE, Robledo C, Garcia JL, et al. Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression prof ling. Ann Oncol 2012; 23: 2138-2146.
21. Higgins RA, Gunn SR, Robetorye RS. Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia. Mol Diagn Ter 2008;12:271-280.
22. Maciejewski JP, Tiu RV, O'Keefe C. Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. Br J Haematol 2009; 146: 479-488.
23. Gunn SR, Mohammed MS, Gorre ME, et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn 2008;10:442-451.
24. Hagenkord JM, Monzon FA, Kash SF, et al. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of af ymetrix 10K2.0, 250K nsp, and SNP6.0 arrays. J Mol Diagn 2010; 12: 184-196.
25. Lehmann S, Ogawa S, Raynaud SD, et al. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer 2008;112:1296-1305.
26. Tyybakinoja A, Vilpo J, Knuutila S. High-resolution oligonucleotide array-CGH pinpoints genes involved in cryptic losses in chronic lymphocytic leukemia. Cytogenet Genome Res 2007; 118: 8-12.
27. Kolquist KA, Schultz RA, Slovak ML, et al. Evaluation of chronic lymphocytic leukemia by oligonucleotide-based microarray analysis uncovers novel aberrations not detected by FISH or cytogenetic analysis. Mol Cytogenet 2011;4:25.
28. O'Malley DP, Giudice C, Chang AS, et al. Comparison of array comparative genomic hybridization (aCGH) to FISH and cytogenetics in prognostic evaluation of chronic lymphocytic leukemia. Int J Lab Hematol 2011;33:238-244.
29. Gunnarsson R, Isaksson A, Mansouri M, et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia 2010; 24: 211-215.
30. Delgado J, Aventin A, Briones J, et al. The use of tetradecanoyl-phorbol acetate-stimulated peripheral blood cells enhances the prognostic value of interphase fluorescence in situ hybridization in patients with chronic lymphocytic leukemia. Genes Chromosomes Cancer 2010;49:327-332.
31. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 2007;370:230-239.
32. Tam CS, Shanafelt TD, Wierda WG, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: The M. D. Anderson and Mayo Clinic experience. Blood 2009; 114: 957-964.
33. Oscier D, Wade R, Davis Z, et al. Prognostic factors identif ed three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010; 95: 1705-1712.
34. Delgado J, Espinet B, Oliveira AC, et al. Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. Br J Haematol 2012 Jan 9. [Epub ahead of print]
35. Dal Bo M, Rossi FM, Rossi D, et al. 13q14 deletion size and number of deleted cells both inf uence prognosis in chronic lymphocytic leukemia. Genes Chromosomes Cancer 2011;50:633-643.
36. Gunnarsson R, Mansouri L, Isaksson A, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 2011; 96: 1161-1169.
37. Forconi F, Rinaldi A, Kwee I, et al. Genome-wide DNA analysis identif es recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. Br J Haematol 2008; 143: 532-536.